FoxP3 ؉ regulatory T cells (Tregs) protect against autoimmunity, type 1 diabetes (T1D) in particular, prompting the hypothesis that a deficiency in Tregs is a critical determinant of diabetes susceptibility in NOD mice. However, tests of this hypothesis have yielded contradictory results. We confirmed that NOD mice, compared with reference strains, do not have a primary deficit in Treg numbers in the lymphoid organs, whether in prediabetic mice of any age or in animals with recent-onset diabetes. NOD Tregs did show a defect in standard in vitro T cell suppression assays, particularly at low suppressor/effector ratios. Gene expression profiling revealed the vast majority of transcripts constituting the ''Treg signature'' to be normally distributed in NOD Tregs versus CD4 ؉ T conventional (Tconv) cells, although there were a few differences affecting one or the other population. According to results from criss-cross experiments, the functional inefficacy was not rooted in NOD Tregs, which suppressed as well as their C57BL/6 (B6) counterparts, but rather in NOD Tconv, which were less prone to suppression than were B6 Tconv cells. They also responded more effectively to anti-CD3/28 monoclonal antibody (mAb) stimulation in vitro or to a natural pancreatic antigen in vivo. This difference was independent of autoimmune inflammation, did not map to the idd3 region, and was not due to the overproduction of interleukin-21 in NOD mice. That the immune dysregulation in this T1D model is rooted in the ability of effector T cells to be regulated, rather than in Tregs themselves, has implications for proposed therapeutic interventions.
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conventional T cells ͉ regulatory T cells ͉ type 1 diabetes T ype 1 diabetes (T1D) is a progressive autoimmune disease in which inflammatory cell invasion of the pancreatic islets promotes destruction of the insulin-producing ␤ cells. The NOD mouse model shares many similarities with autoimmune diabetes in humans, including the presence of pancreas-specific autoantibodies, the importance of autoreactive CD4 ϩ and CD8 ϩ T cells, and a strong component of genetic susceptibility (1) .
Several cell populations with immunoregulatory properties have an impact on the progression of T1D, exhibiting either protective or exacerbating effects. These populations include natural killer T cells (NKT cells), CD8␣␣ T cells, and other less well characterized cell types (2, 3) . However, so far, most attention has been paid to regulatory cells initially characterized by their CD25 hi and CD45RB lo phenotype (4) , and more recently and more specifically by their expression of the forkhead family transcription factor FoxP3 (5, 6) . FoxP3
ϩ Tregs have the ability to dampen the activities of conventional T cells in vitro and in vivo, their genetic deficiency or experimental ablation resulting in massive lymphoproliferation and multiorgan autoimmunity (7, 8) . Moreover, Tregs control a number of autoimmune, allergic, anti-tumor, and anti-infectious responses (9, 10) .
Tregs clearly influence the development of T1D. Their experimental depletion or a genetic deficiency in their numbers or activity promote a more aggressive disease (11), whereas their transfer or therapeutic enhancement has protective effects (11) (12) (13) , which is potentially of great promise in the clinic. On the other hand, it is not clear whether primary or secondary deficiencies, genetically programmed or developing indirectly, are an intrinsic element of natural pathogenesis.
Two major questions pertaining to the relationship between Tregs and autoimmune diabetes beg to be answered. First, is there a primary, genetically encoded deficiency in their representation or function that contributes importantly to susceptibility to pancreatic islet autoimmunity? This has been a debated issue. Several studies have suggested primary defects in the number of Tregs in NOD mice (11, 14, 15) , but these results were not reproduced by a number of groups (16) (17) (18) (19) (20) . Some of the discrepancies may stem from the use of different markers to identify the Treg population, particularly as the earlier studies relied on CD25. It is now known that a proportion of FoxP3 ϩ cells is CD25 dull/Ϫ (21), which is a particular issue for NOD mice, whose component of CD25 lo Tregs is unusually high (22) . We recently reported that inbred mice have a wide range of Treg frequencies, and that the NOD genetic background is conducive to efficacious generation of Tregs in the thymus, whether in response to agonist ligands or in nonmanipulated conditions (22) . It was recently suggested that the idd3 locus, which includes the Il2 and Il21 genes, contributes to susceptibility to T1D by influencing the production of interleukin (IL)-2 (23), a cytokine key to Treg homeostasis (24, 25) . The impact of idd3 on T cell activation and diabetes incidence in the 8.3 T cell receptor (TCR) transgenic model could be phenocopied by an Il2 haploinsufficiency, and Treg numbers and activity has seemed to be tracked with the amount of IL-2 (23) .
The second unanswered question pertains to alterations manifest at a later stage, accompanying the transition to terminal islet destruction and the development of overt diabetes. Several studies have reported that, rather than inborn Treg defects in the NOD strain, an age-related decline in their function was associated with the progression of disease (17) (18) (19) (20) 26) . There have been some discrepancies in these observations in that some investigators observed Treg deficiencies in all lymphoid organs or at various times in the course of disease (17) (18) (19) (20) , whereas Tang et al., using microscopic evaluation, saw this drop only in the pancreas of mice with recent-onset diabetes and not elsewhere (26) .
We have re-assessed these controversial issues exploiting a newly available resource: Tregs from FoxP3-GFP indicator murine lines of NOD genetic background were evaluated in cytofluorimetric, functional, and genomic assays.
in the proportion of CD4 ϩ CD25 ϩ Tregs in NOD mice, and/or an age-related decline in their frequency or activity. On the other hand, our previous work demonstrated that this T1D model does not have a global defect in the generation of Tregs-if anything, the opposite-as the NOD genetic background favors their thymic selection (22) , consistent with the findings of several other groups.
To explore the Treg population in our current colony of NOD mice, we evaluated their percentage among splenic CD4 ϩ cells over time. A normal proportion of FoxP3 ϩ cells was observed in 6-week-old NOD mice, slightly higher than that found in the diabetes-resistant B6 strain (Figs. 1A, 1B) . The robust Treg representation in NOD mice was true of all lymph nodes (LN) analyzed (Fig. 1B) , and fell in the range of values for normal inbred strains (22) . A detailed time-course analysis, from neonates to 20-week-old mice, documented an increase in the proportion of Tregs with age, parallel in NOD, B6, and B6.H2 g7 (B6g7) major histocompatibility complex (MHC) congenic mice (Fig. 1C) , in accordance with other recent reports (16, 26) . Moreover, the proportion of FoxP3 ϩ cells in mice with recentonset diabetes was similar to that in aged-matched prediabetic animals. These observations also translate to a normal (at least) ratio of Tregs to CD8 ϩ cells, given that NOD mice have a slightly smaller CD8 ϩ T cell compartment than B6 animals (not shown). The functional competence of Tregs in NOD mice has been a point of debate (27) , one that we considered worth revisiting in the context of our colony. Tregs were sorted from NOD-and B6-background mice as GFP ϩ cells (from parallel backcrosses of the FoxP3 GFP reporter (21) , crossed in parallel six to 10 generations onto the B6 or NOD background), and were introduced into a standard in vitro assay of their ability to suppress the proliferation of effector cells activated with anti-CD3 mAb (28) .
CD4
ϩ GFP ϩ cells were titrated into background-matched cultures of responder CD4 ϩ CD25 Ϫ Tconv cells stimulated with plate-bound anti-CD3. Tregs from NOD mice proved quite effective (Fig. 1D) , although in repeated experiments there was slightly less suppression than with their B6 counterparts at the lower suppressor/target ratios, amounting to a roughly twofold shift in efficacy at the low ratios. Similar results were obtained with cells from older prediabetic mice 12-20 weeks of age (not shown).
Thus, the NOD mice that we examined harbor normal numbers of Tregs; but these cells have a defect in their suppressive activity measured in in vitro suppression assays.
Gene-Expression Divergences in NOD Mice. Given this difference in suppressive activity, we used gene-expression profiling to characterize the functional potential of NOD Tregs at the molecular level, asking whether any differences in the canonical ''Treg signature'' transcripts were discernible. Treg and Tconv cells were sorted (as CD4 ϩ CD25 hi and CD4 ϩ CD25 Ϫ cells, respectively) from spleens of 6 -7-week-old NOD and diabetesresistant B6g7 MHC-congenic mice, and RNA was prepared and amplified for hybridization to Affymetrix M430 2.0 microarrays (three independent replicates). To compare the Treg signature of B6g7 and NOD cells, we calculated the fold-change ratio of the Treg to Tconv cell expression values and plotted the averages for each probe set ( Fig. 2A) . A consensus Treg signature was previously compiled from several independent analyses (29) , and the color coding of Fig. 2 A highlights genes twofold over-or underexpressed in Treg relative to Tconv cells. The vast majority of the Treg signature elements were equally represented in B6g7 and NOD cells, most transcripts lining up along the diagonal, i.e., showing the same relative enrichment (or depletion) in Tregs in the two strains. Included were many canonical Treg transcripts such as Foxp3 (predictably, as the intensity of FoxP3 staining was identical in both strains; not shown), Il2ra and Ctla4, as well as genes that are typically underexpressed in Tregs, such as Pde3b and Pdlim4. However, a small number of genes were overexpressed in NOD Treg relative to Tconv cells but not vice versa, nor in B6g7 Tregs or (Fig. 2 A, zones a and c) , or were underexpressed in Tregs of only one of the strains (zones b and d). Because the signature was defined by the ratio of Treg to Tconv cell expression, any differential in the B6g7 and NOD ratios could reflect strain-specific dissimilarities in Tregs, Tconv cells, or both. This point was investigated via the heat-map representation of expression differences in the whole gene set (Fig. 2B) . In zones a and b, differences in Tregs were responsible for most of the strain specificity. For instance, the overrepresentation of Hod or P2rx7 transcripts, which encode a transcription factor and a member of the P2 purinoreceptor family, respectively, was missing in the NOD strain. In contrast, most of the observed differences in zones c and d were related to strain-specific dissimilarities in Tconv cells. For instance-and perhaps most strikingly, given its implication as a growth and differentiation factor for CD4 ϩ cells-IL21 transcripts were overrepresented in Tconv cells of NOD origin. This result confirms and extends previous reports of a higher expression of IL-21 in NOD mice (23, 30, 31) .
Thus, the Treg/Tconv axis in NOD mice exhibits most of its usual distinguishing characteristics, but with some discrete and suggestive differences from the B6 counterpart. Most relevant to the functional relationship, these divergences were found in both Treg and Tconv cells.
Defective Suppression Emanating from Tconv, Not Treg, Cells. The transcriptional differences suggested three possible explanations for the relative inefficiency of suppression in NOD cultures: less potent Tregs, more suppression-resistant effector T cells, or a combination of the two. Therefore we tested, independently, in criss-cross experiments, the two sides of the Treg/Tconv axis. Because it allows better distinction of responder cells, the carboxyfluorescein succinimidyl ester (CFSE) dilution assay was adopted in these and subsequent experiments. Tregs from the NOD or B6g7 background were sorted, and were titrated into a suppression assay against a given Tconv cell population labeled with CFSE. Tregs from the two origins demonstrated a very similar suppressive activity when NOD effector T cells were assayed (Fig. 3A) . In contrast, Tregs from both strains showed a differential ability to suppress Tconv cells from NOD vs. B6g7 mice, the effectors of NOD origin being less sensitive to dampening (Figs. 3B, 3C ). This resistance to suppression correlated with a distinctly higher baseline rate of proliferation by NOD Tconv cells, evident from both CFSE dilution profiles and division plots (Figs. 3D, 3E) . We also evaluated IL-2 concentrations in the supernatants of the four culture types: higher IL-2 production tracked with the source of the Tconv cell input, whereas the origin of the Tregs made no difference (Fig. 3F) . Thus, the differential performance of B6 and NOD cells in in vitro suppression assays stems not from the Treg side but rather from overreactivity of the NOD Tconv cells, rendering them relatively insensitive to suppression.
The higher responsiveness and relative refractoriness to suppression of NOD Tconv cells could be cell intrinsic or might be due to intercrine influences, such as a higher production of cytokines or costimulatory factors. To address this issue, we sorted Tconv cells from the two strains, labeled them with CFSE, and stimulated them with anti-CD3/CD28 mAbs, alone or in combination (distinguishing cells of NOD and B6g7 origin through their CD45.1 and CD45.2 allotypic markers). In the mixed-strain culture, NOD Tconv cells proliferated as actively as when incubated alone, whereas the response of B6g7 cells was markedly enhanced relative to when they were cultured in isolation (Figs. 4A, 4B) . Thus, an intercrine factor produced by NOD Tconv cells seemed to support the higher proliferation of other responders with which they were cultured. This enhancement could potentially reflect the overproduction of IL-2 by NOD Tconv cells upon activation. We tested this hypothesis by performing the same coculture experiments in the presence of high doses of an anti-IL-2 antibody (Fig. 4C) . Although the antibody decreased the proliferative response overall, it spared the ability of NOD Tconv cells to enhance the response of cocultured B6g7 Tconv cells. In preliminary experiments with transwell chambers, this effect disappeared, arguing for either a mediator requiring cell-cell contact, or a cytokine acting at a short distance (not shown).
Origin of NOD Tconv Cell Overresponsiveness. We then attempted to track the root of the overresponsiveness of NOD Tconv cells. It proved not to be the indirect result of ongoing autoimmunity, as the difference between NOD and B6g7 responders in the in vitro suppression assay was observed in 3-week-old mice (when the autoimmune process has barely started) and in 16-week-old prediabetic animals (Fig. 5A) . Moreover, the Tconv cells from NOD.E␣16 mice, genetically identical to NOD animals but protected from insulitis by an MHC class II E␣ transgene (32), were also hyperresponsive (Fig. 5B) . The difference between NOD and B6g7 effector T cells appeared quite early in differ- entiation, as mature CD4 ϩ CD8 Ϫ CD24 low thymocytes from NOD mice were also more responsive than their B6g7 counterparts (Figs. 5C, 5D ). Thus, this element likely represents a basic feature of signaling in T cells of NOD mice rather than a secondary adaptation to particular homeostatic conditions in secondary lymphoid organs.
The overresponsiveness of NOD Tconv cells did not map to the MHC, as the differential was observed when comparing cells from NOD mice with either B6 or B6g7 cells. IL-21 made a particularly attractive candidate for driving the difference, given its overexpression in NOD Tconv cells and its growth-enhancing properties (33) . In addition, Peluso et al. reported that IL-21 renders human CD4 ϩ CD25
Ϫ T cells refractory to in vitro suppression (34) . IL21 maps to the idd3 diabetes-susceptibility region, and we confirmed that the higher IL-21 expression in NOD Tconv cells (23, 30, 31) was indeed a function of that locus, as NOD.idd3 b/b congenic mice exhibited the same low level of IL-21 transcripts as did B6g7 mice according to reverse transcriptase-polymerase chain reaction (RT-PCR) quantification (data not shown). Yet, Tconv cells from NOD.idd3 b/b mice showed the same proliferation profile as did NOD Tconv cells (Fig. 6A) , demonstrating that the idd3 locus was not responsible for the observed difference. Furthermore, the addition of IL-21-blocking antibody to either NOD or B6g7 cultures did not affect the proliferation of effector T cells in this assay system (Fig. 6B) . Thus, the overresponsiveness of NOD Tconv cells does not map to the idd3 locus and is not due to the IL-21 cytokine that it encodes.
Overresponsiveness of NOD Tconv Cells in Vivo. Next we determined whether the differences manifested after anti-CD3 mAb stimulation in vitro also applied to responses to normal autoantigens in vivo, using as reporters Tconv cells from BDC2.5 TCR transgenic mice, reactive to a natural islet cell autoantigen (35) . Tconv cells were purified as CD4 ϩ CD25 Ϫ cells from either BDC2.5/NOD or BDC2.5/B6g7 mice, and were transferred after labeling into (NODxB6g7) F1 recipients harboring a full complement of Tregs. As expected (36), proliferation, signified by CFSE dilution, was observed only in the draining pancreatic LNs and not in irrelevant LNs. The antigen-specific response 3 days after transfer was significantly greater for BDC2.5/NOD than for BDC2.5/B6g7 donors (Fig. 7) . Thus, the in vitro difference in Tconv cell responses also applied in vivo. On the other hand, co-transfers of cells of both origins yielded a dominance of the low responder phenotype of the B6g7 background.
Discussion
The NOD mouse strain has a general propensity to autoimmune disease that extends beyond the diabetes for which it is primarily known. NOD mice are very susceptible to spontaneous thyroiditis and celiac disease, to induced experimental allergic encephalomyelitis, and to the pathologic conditions imparted by a deficiency in Aire. Some of this susceptibility originates from defective T cell tolerance induction in the thymus (37-39); but most likely it also reflects, at least in part, deficient control of strated that this is indeed the case, but that the defect lies in an overactivity of Tconv cells, not in the Treg side of the balance. The absence of a numeric defect in NOD Tregs, either intrinsic or accompanying progression to diabetes, contrasts with some prior reports of Treg deficits in NOD mice, either at all ages or in advanced prediabetic mice only. Part of the discrepancy is likely caused by nondiscriminatory reagents used in several of the early studies (e.g., anti-CD25, FoxP3 mRNA). Indeed, our data are in line with several recent reports that showed no significant numeric defect in Tregs of NOD mice over time (16, 26) . They are also consistent with our previously published broad analysis of inbred strains of the Mouse Phenome Database, and with the observation that the NOD genetic background actually particularly favors the thymic generation of Tregs (22) .
Instead, the quantitative imbalance in the NOD Treg/Tconv axis could be traced to a higher responsiveness of Tconv cells, and hence a greater refractoriness to Treg action. Because of a higher baseline level of responsiveness, NOD Tconv cells required more Treg input than B6g7 Tconv cells did to be dampened to an equivalent level. Robustly proliferating T cells more effectively acquire the functional features of pathogenic T cells, effector functions reflected by the higher levels of IL-2 that they produce upon stimulation. Consistent with this view, more rapidly proliferating T cells are more destructive and rapidly induce diabetes in vivo (30) . This difference appeared intrinsic to the NOD genome, did not vary with the age of the mice, and was not a secondary consequence of the autoimmune process. As such, it differs from the observations of You et al., who reported a decreased susceptibility to Treg action by Tconv cells of aged NOD mice relative to younger animals but provided no comparison with diabetes-resistant strains (19) .
The hyperresponsiveness of NOD Tconv cells did not map to the idd3 locus on Chr3, nor did it seem to reflect the known overproduction of IL-21 in NOD mice (30) . It will certainly be interesting to map its genomic origin, in particular whether it coincides with the Treg control locus identified by the Morel group in the lupus context (40) . Although we found no deficit in the Treg cells of NOD mice, our results are still compatible with the data of Yamanouchi et al., who found a lower level of Tregs in NOD versus NOD.idd3 b/b congenic mice, which they attributed to a lower production of IL-2 by the NOD-derived allele at idd3 (23) . First, the influence of the idd3 region on Treg numbers that they described was rather limited (2-3%); second, the combined influence of genetic variants fixed in the NOD genome might compensate for the influence of idd3 in isolation, leading to robust IL-2 production and normal numbers of Tregs.
As concerns the human context, a first report claimed clear differences in the frequency of CD4 ϩ CD25 hi Tregs in blood lymphocytes from T1D patients versus healthy controls (41), but subsequent publications did not reproduce this divergence (42) (43) (44) . On the other hand, a recent study from Schneider et al. (45) , comparing diabetes patients and nondiabetic controls, demonstrated that effector T cells from the patients were more refractory to Treg inhibition than were those from age-and HLA-matched controls. Thus, an imbalance of the Treg/Tconv axis reflecting an issue on the Tconv side may be a common theme across species.
It will be important to keep this in mind when considering immunomodulating strategies based on infusing or eliciting Tregs in patients, as is currently contemplated in a number of contexts (46) .
Materials and Methods
Mice. NOD/LtDOI (NOD), C57BL/6.H2g7 (B6g7), NOD.E␣16, and NOD.FoxP3 GFP and B6.FoxP3 GFP reporter mice (the latter backcrossed for at least six generations) were bred in the specific-pathogen-free facilities at the Joslin Diabetes Center or the Jackson Laboratory or purchased from Taconic (Germantown, NY) for NOD.idd3 b/b congenic line 1098.
Cell Sorting and Flow Cytometry. Cells were sorted as B220 Ϫ CD8 Ϫ CD11b Ϫ CD4 ϩ and either CD25 hi (Treg) or CD25 Ϫ (Tconv) (Moflo) from B6g7 or NOD mice, or as CD4 ϩ GFP ϩ Treg and CD4 ϩ GFP Ϫ Tconv cells from NOD.FoxP3 GFP and B6.FoxP3 GFP reporter mice (21) . Postactivation analysis assessed CD4, CD45.1, and CD45.2 expression. FoxP3 expression was evaluated by intracellular staining with the FJK-16s mAb (eBioscience, San Diego, CA). Cells were analyzed using the LSRII instrument and FloJo software.
Proliferation Assays. For stimulation and suppression experiments, CD4 ϩ CD25 Ϫ or CD4 ϩ GFP Ϫ responder cells were labeled by incubation at 10 6 /ml in RPMI 1640 with 10 mol/l CFSE (Molecular Probes, Eugene, Oregon) at 37°for 20 min, washed and resuspended in complete culture medium (RPMI 1640, 10% fetal calf serum, 2 mmol/l L-glutammine, penicillin/streptomycin), and cultured at 2.5 ϫ 10 4 -10 5 cells/well in a roundbottom, 96-well plate (Corning, Corning, NY). Stimulation was effected by addition of anti-CD3/CD28-coated beads (Dynal, Carlsbad, CA), or by precoating the plates with affinity purified antiCD3 (1.5 g/ml). Proliferation was assessed by incorporation of 3 H-thymidine (1 Ci in the last 16 hours of culture) or by flow-cytometric analysis of CFSE dilution. In the mixed cultures, NOD and B6g7 cells were discriminated by expression of the allotypic markers CD45.1 (NOD) and CD45.2 (B6g7). Blocking anti-IL-21 (polyclonal IgG, R&D Systems, Minneapolis, MN) was added at 2.5-10 g/ml, blocking anti-IL-2 (polyclonal IgG, R&D Systems) at 5 g/ml. In vivo proliferation assays were performed as described (36) .
Microarray Analysis. Splenocytes were collected from 6 -7-week-old NOD and B6g7 mice, presorted with anti-CD4 MACS beads, and double-sorted as CD4 ϩ CD25 hi (Treg) or CD4 ϩ CD25 Ϫ (Tconv) directly into TRIzol reagent. RNA was amplified for two rounds using the MessageAmp aRNA kit (Ambion, Austin, TX), followed by biotin labeling using the BioArray High Yield RNA Transcription Labeling Kit (Enzo Diagnostics, NY). The resulting cRNAs (three independent replicates) were hybridized to M430 2.0 chips (Affymetrix, Santa Clara, CA). The image reads were processed through Affymetrix software to obtain raw .cel files. These were background corrected and normalized using the RMA algorithm implemented in the GenePattern software package (41) , and replicates were averaged. To avoid noise from probe sets with expression values at background levels, an expression threshold was calculated (for a probability of nonexpression Ͼ0.95 based on the chip's negative controls), and probe sets were ignored in the analysis if none of the conditions showed a value above that threshold. A consensus Treg signature was compiled by calculating the average fold-change ratios in datasets generated in two independent studies comparing (1) CD4 ϩ CD25 ϩ FoxP3 GFPϩ vs. CD4 ϩ CD25 Ϫ FoxP3 GFPϪ LN cells (21) , and (2) CD4 ϩ CD25 ϩ and CD4 ϩ CD25 Ϫ LN cells from B6 mice. Genes were considered part of the signature if they were differentially expressed twofold or more in both data sets. Microarray data have been submitted and are available from the NCBI/GEO repository (accession number GSE6813).
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